The composition of the intestinal microbiome may predict clinical outcomes of CAR-T cell therapy for lymphoma, which could inform microbiota-based intervention strategies.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Peled, J. U. et al. New Engl. J. Med. 382, 822–834 (2020).
Smith, M. et al. Nat. Med. 28, 713–723 (2022).
Gopalakrishnan, V. et al. Science 359, 97–103 (2018).
Routy, B. et al. Science 359, 91–97 (2018).
Stein-Thoeringer, C. K. Nat. Med. https://doi.org/10.1038/s41591-023-02234-6 (2023).
Weber, D. et al. Biol. Blood Marrow Transplant 23, 845–852 (2017).
van Lier, Y. F. et al. Sci. Transl. Med. 12, eaaz8926 (2020).
Davar, D. et al. Science 371, 595–602 (2021).
Z.D. receives research support from Incyte, Corp., Regimmune, Corp and Taiho Oncology, Inc. and has received consulting fees from Kadmon Corp., Omeros Corp., Incyte, Corp., MorphoSys AG, Inhibrx and PharmaBiome AG. M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (some licensed to Promab) and University of Pennsylvania (some licensed to Novartis). M.V.M. receives Grant/Research support from: Kite Pharma. M.V.M. has served as a consultant for multiple companies involved in cell therapies. M.V.M. holds Equity in 2SeventyBio, Century Therapeutics, Neximmune, Oncternal and TCR2. M.V.M. is on the Board of Directors of 2Seventy Bio.
Rights and permissions
About this article
Cite this article
DeFilipp, Z., Maus, M.V. Linking the microbiome to CAR-T cell responses. Nat Med 29, 785–786 (2023). https://doi.org/10.1038/s41591-023-02272-0